Neurogene Inc. (NGNE)
NASDAQ: NGNE · Real-Time Price · USD
27.45
+0.40 (1.48%)
At close: Apr 28, 2026, 4:00 PM EDT
27.99
+0.54 (1.97%)
After-hours: Apr 28, 2026, 5:51 PM EDT
Neurogene Market Cap
Neurogene has a market cap or net worth of $428.65 million as of April 28, 2026. Its market cap has increased by 161.02% in one year.
Market Cap
428.65M
Enterprise Value
169.53M
1-Year Change
161.02%
Ranking
Category
Stock Price
$27.45
Market Cap Chart
Since December 19, 2023, Neurogene's market cap has increased from $193.64M to $428.65M, an increase of 121.37%. That is a compound annual growth rate of 40.06%.
Market Cap History
| Date | Market Cap | % Change |
|---|---|---|
| Apr 28, 2026 | 428.65M | 34.34% |
| Dec 31, 2025 | 319.09M | -6.03% |
| Dec 31, 2024 | 339.58M | 36.64% |
| Dec 29, 2023 | 248.52M | 28.34% |
| Dec 19, 2023 | 193.64M | - |
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
| Company | Market Cap |
|---|---|
| Eupraxia Pharmaceuticals | 444.11M |
| Assembly Biosciences | 436.22M |
| Benitec Biopharma | 432.30M |
| Atea Pharmaceuticals | 427.04M |
| Lexeo Therapeutics | 416.74M |
| Invivyd | 412.89M |
| Century Therapeutics | 405.13M |
| Neumora Therapeutics | 404.65M |